BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30980316)

  • 1. Assessing the value of a censored surrogate outcome.
    Parast L; Tian L; Cai T
    Lifetime Data Anal; 2020 Apr; 26(2):245-265. PubMed ID: 30980316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust estimation of the proportion of treatment effect explained by surrogate marker information.
    Parast L; McDermott MM; Tian L
    Stat Med; 2016 May; 35(10):1637-53. PubMed ID: 26631934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating surrogate marker information using censored data.
    Parast L; Cai T; Tian L
    Stat Med; 2017 May; 36(11):1767-1782. PubMed ID: 28088843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust approach to combining multiple markers to improve surrogacy.
    Wang X; Parast L; Han L; Tian L; Cai T
    Biometrics; 2023 Jun; 79(2):788-798. PubMed ID: 35426444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying the feasibility of shortening clinical trial duration using surrogate markers.
    Wang X; Cai T; Tian L; Bourgeois F; Parast L
    Stat Med; 2021 Dec; 40(28):6321-6343. PubMed ID: 34474500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing treatment effects with surrogate survival outcomes using an internal validation subsample.
    Zee J; Xie SX;
    Clin Trials; 2015 Aug; 12(4):333-41. PubMed ID: 25976869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity.
    Guo X; Bourgeois FT; Cai T
    Stat Methods Med Res; 2024 May; ():9622802241247719. PubMed ID: 38717356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semiparametric inference for surrogate endpoints with bivariate censored data.
    Ghosh D
    Biometrics; 2008 Mar; 64(1):149-56. PubMed ID: 17651457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate markers and joint models for longitudinal and survival data.
    Taylor JM; Wang Y
    Control Clin Trials; 2002 Dec; 23(6):626-34. PubMed ID: 12505241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accommodating missingness when assessing surrogacy via principal stratification.
    Elliott MR; Li Y; Taylor JM
    Clin Trials; 2013; 10(3):363-77. PubMed ID: 23553326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating multiple surrogate markers with censored data.
    Parast L; Cai T; Tian L
    Biometrics; 2021 Dec; 77(4):1315-1327. PubMed ID: 32920821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new proportion measure of the treatment effect captured by candidate surrogate endpoints.
    Kobayashi F; Kuroki M
    Stat Med; 2014 Aug; 33(19):3338-53. PubMed ID: 24782344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using a surrogate marker for early testing of a treatment effect.
    Parast L; Cai T; Tian L
    Biometrics; 2019 Dec; 75(4):1253-1263. PubMed ID: 31009073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials.
    Speiser JL; Ambrosius WT; Pajewski NM
    Clin Trials; 2023 Oct; 20(5):507-516. PubMed ID: 37243355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of longitudinal surrogate markers.
    Agniel D; Parast L
    Biometrics; 2021 Jun; 77(2):477-489. PubMed ID: 32506496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models.
    Taylor JM; Conlon AS; Elliott MR
    Clin Trials; 2015 Aug; 12(4):317-22. PubMed ID: 25490988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonparametric estimation in an illness-death model with component-wise censoring.
    Eaton A; Sun Y; Neaton J; Luo X
    Biometrics; 2022 Sep; 78(3):1168-1180. PubMed ID: 33914913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.
    Conlon AS; Taylor JM; Elliott MR
    Biostatistics; 2014 Apr; 15(2):266-83. PubMed ID: 24285772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semiparametric transformation models for semicompeting survival data.
    Lin H; Zhou L; Li C; Li Y
    Biometrics; 2014 Sep; 70(3):599-607. PubMed ID: 24749525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing heterogeneity in surrogacy using censored data.
    Parast L; Tian L; Cai T
    Stat Med; 2024 May; ():. PubMed ID: 38812276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.